Skip to main content

FDA grants Ranbaxy final approval for generic Biaxin

10/12/2007

HARYANA, India The Food and Drug Administration has granted final approval to Ranbaxy to manufacture and market generic Biaxin (clarithromycin).

The oral suspension of Biaxin, available in a 125 mg/mL and 250 mg/mL is used for treatment of tonsillitis, community acquired pneumonia, uncomplicated skin and skin structure infections, and disseminated mycobacterial infections.

The drug had annual sales of $25.3 million during the 12-month period ending in June, according to IMS Health data.

X
This ad will auto-close in 10 seconds